These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 3246814)
21. Histological effects of endocrine therapy for prostatic cancer in relation to clinical course. Isaka S; Teshima S; Akakura K; Igarashi T; Murakami S; Shimazaki J Jpn J Clin Oncol; 1989 Sep; 19(3):258-64. PubMed ID: 2554026 [TBL] [Abstract][Full Text] [Related]
22. [Treatment of prostatic cancer: medroxyprogesterone acetate, diethylstilbestrol and cyproterone acetate. Provisional report of a random study by the genito-urinary cooperative group of the EORTC]. Pavone-Macaluso M; Martínez-Piñeiro JA; de Voogt H; Lardennois B; Nasta A; Zolfanelli R; Barasolo E; De Pauw M; Suciu S; Sulvester R Arch Esp Urol; 1982; 35(5):304-11. PubMed ID: 6217788 [No Abstract] [Full Text] [Related]
23. A phase II study of high-dose estrogens (diethylstilbestrol diphosphate) in prostate cancer. Citrin DL; Kies MS; Wallemark CB; Khandekar J; Kaplan E; Camacho F; Lind R Cancer; 1985 Aug; 56(3):457-60. PubMed ID: 4005808 [TBL] [Abstract][Full Text] [Related]
25. [Prognostic significance of mutually exclusive expression of ERG and SPINK1 in endocrine-treated prostatic cancer]. Teng L; Gao W; Lu D; Xu J; Zhao L Zhonghua Bing Li Xue Za Zhi; 2014 Mar; 43(3):149-53. PubMed ID: 24842011 [TBL] [Abstract][Full Text] [Related]
26. [Clinical and pathological study of prostate cancer using Gleason's classification]. Nemoto R; Uchida K; Kiriyama I; Koiso K; Harada M Nihon Gan Chiryo Gakkai Shi; 1987 Dec; 22(10):2325-30. PubMed ID: 3449581 [No Abstract] [Full Text] [Related]
27. Prostatic carcinoma with emphasis on Gleason's Grading: an institution based experience. Ahmed Z; Muzaffar S J Pak Med Assoc; 2002 Feb; 52(2):54-6. PubMed ID: 12073709 [TBL] [Abstract][Full Text] [Related]
28. Cyproterone acetate versus medroxyprogesterone acetate versus diethylstilbestrol in the treatment of prostate cancer: results from EORTC Study 30761. Pavone-Macaluso M; Ingargiola GB; de Voogt H; Viggiano G; Barasolo E; Lardennois B; De Pauw M; Sylvester R Prog Clin Biol Res; 1987; 243A():379-82. PubMed ID: 2958862 [No Abstract] [Full Text] [Related]
29. Expression of cytokines enhancing the osteoclast activity, and parathyroid hormone-related protein in prostatic cancers before and after endocrine therapy: an immunohistochemical study. Sugihara A; Maeda O; Tsuji M; Tsujimura T; Nakata Y; Akedo H; Kotake T; Terada N Oncol Rep; 1998; 5(6):1389-94. PubMed ID: 9769374 [TBL] [Abstract][Full Text] [Related]
30. Endocrine therapy: predictors of response to prostatic cancer. Geller J; Albert JD Semin Urol; 1983 Nov; 1(4):291-7. PubMed ID: 6399615 [No Abstract] [Full Text] [Related]
31. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. Pavone-Macaluso M; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R J Urol; 1986 Sep; 136(3):624-31. PubMed ID: 2942707 [TBL] [Abstract][Full Text] [Related]
32. [Scintigraphic control of bone metastases of prostatic cancer treated with cytonal and cyclophosphamide]. Grossmann J; Weiss M; Deckart H; Raatzsch H Radiobiol Radiother (Berl); 1988; 29(6):736-8. PubMed ID: 3253797 [No Abstract] [Full Text] [Related]
33. [Flow cytometry in prostate cancer. Evaluation of its feasibility for biopsy specimens and correlation with grading]. Ferrara G; Monaco R; Capasso A; Bellomo PF; Fruttero A; Pugno F; Nappi O; Ruà S Pathologica; 1998 Feb; 90(1):14-9. PubMed ID: 9628974 [TBL] [Abstract][Full Text] [Related]
34. [Plasma levels of fosfestrol and its monophosphate, of diethylstilbestrol and its monoglucuronide following intravenous administration in patients with metastatic prostatic carcinoma]. Oelschläger H; Rothley D; Dunzendorfer U Arzneimittelforschung; 1984; 34(10):1333-6. PubMed ID: 6542793 [TBL] [Abstract][Full Text] [Related]
35. [Gleason's score: update in 2008]. Molinié V Ann Pathol; 2008 Oct; 28(5):350-3. PubMed ID: 19068389 [TBL] [Abstract][Full Text] [Related]
36. [Prostatic carcinoma: histoprognosis, prognostic value of Gleason's index]. Saint-André JP; Rousselet MC; Six P; Bertrand G; Soret JY Bull Cancer; 1985; 72(5):414-22. PubMed ID: 4074910 [TBL] [Abstract][Full Text] [Related]
37. [Honvan-high-dose therapy of prostatic carcinoma with metastases: early complications and value of prophylaxis against thrombosis]. Heinz A; Meyer WW; Hallwachs O Urologe A; 1982 Jul; 21(4):232-4. PubMed ID: 6890263 [TBL] [Abstract][Full Text] [Related]
38. Prediction of Prognosis for Prostatic Adenocarcinoma by Combined Histological Grading and Clinical Staging. Gleason DF; Mellinger GT; J Urol; 2017 Feb; 197(2S):S134-S139. PubMed ID: 28012760 [No Abstract] [Full Text] [Related]
39. [Estrogen therapy of prostatic cancer. 76 cases of previously undiagnosed prostatic cancer treated with F6066 (bis-(p-acetoxyphenyl)cyclohexylidenemethane) and diethylstilbestrol--a double-blind study]. Carstensen HE; Olsen CE; Sele V; Brorson I; Jensen E; Nissen NI; Fabricius J Nord Med; 1969 Jan; 81(4):111-4. PubMed ID: 4888811 [No Abstract] [Full Text] [Related]
40. A 125I-radioimmunoassay for diethylstilbestrol in serum of patients with prostatic cancer treated with stilphostrol. Economou EV; Livaniou E; Evangelatos GP; Ithakissios DS Clin Chim Acta; 1993 Jul; 216(1-2):81-90. PubMed ID: 8222276 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]